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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neuro-
degenerative disorder caused by a CAG repeat expansion in the 
gene encoding the protein huntingtin. Patients characteristical-
ly develop motor, cognitive, and behavioral deficits during the 
course of the disease.1 Other features include sleep and circa-
dian rhythm disorders2-4 and symptoms of cognitive decline,5,6 
as well as disturbances in peripheral circadian pathways such as 
the liver’s metabolic cycle.7 These disturbances in intrinsic cir-
cadian rhythmicity and a delayed phase position of hormones 
such as melatonin and cortisol3,8 suggest a disorder of the en-
dogenous biological masterclock, the suprachiasmatic nucleus 
(SCN), in patients with HD similar to SCN pathology in the 
R6/2 transgenic mouse model of HD.8-11 One of the principal 
circadian hormones released under the influence of the SCN is 
melatonin, which in turn has a feedback mechanism on the SCN 
during which its actions are mediated by the melatonin 1 and 2 
receptors (MT1 and MT2).12,13
Elucidation of the mechanisms underlying sleep and circa-
dian rhythm disturbances in patients with HD is of great im-
portance because restoration of sleep-wake cycles may not only 
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improve quality of life, but might also ameliorate cognitive and 
motor dysfunction.10,11 To test the hypothesis that the biologi-
cal clock is affected in patients with HD, we directly assessed 
the functional integrity of the SCN in HD and control brains 
by determining the expression of two major regulatory neuro-
peptides, vasoactive intestinal polypeptide (VIP) and arginine 
vasopressin (AVP), as well as MT1 and MT2, which are crucial 
for SCN entrainment.
METHODS
Postmortem Material
All brain material for patients with HD and control subjects 
was obtained through the Netherlands Brain Bank (NBB) and 
consisted of formalin-fixed, paraffin-embedded hypothalamic 
material (patients with HD n = 8, control subjects n = 8). Control 
subjects were matched to patients with HD for sex, age, clock 
time and month of death, postmortem delay, and fixation time 
(Table 1). Different control subjects were used for VIP/AVP 
and MT1/MT2 analysis when insufficient hypothalamic sections 
were available from the same control subject while maintaining 
adequate matching for the putative confounding factors men-
tioned previously. Written informed consent for brain autopsy 
as well as for the use of brain material and medical records for 
research purposes was acquired by the NBB from patients or 
their next of kin. This study was approved by the institutional 
review board of the NBB.
The diagnosis of HD was clinically and neuropathologically 
confirmed in all patients. Additionally, the diagnosis was geneti-
cally confirmed (CAG repeat ≥ 39) in all but one patient (NBB 
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92-105). This patient, however, had a positive family history and 
the clinical features of HD, as well as a confirmed Vonsattel grade 
II HD neuropathology. In Vonsattel grade II and higher grades of 
HD neuropathology, the changes in the caudate nucleus are char-
acterized by atrophy, neuronal loss, and fibrillary astrocytosis, 
whereas the globus pallidus in stage II is still relatively spared.14 
Exclusion criteria for control subjects were primary neurologic 
and/or psychiatric disorders and glucocorticoid therapy during 
the 2 months before death because glucocorticoids can influence 
the activity of the SCN.15 Neuroleptic drugs were not considered 
an exclusion criterion for patients with HD because depletion of 
dopamine has no effect on clock gene expression in the SCN.16 
Unfortunately, no information was available on type or degree of 
sleep and circadian disorders in the patients with HD.
Immunocytochemistry
The immunocytochemical procedures have been described 
previously.17 In short, every 25th section (6 μm) of the SCN was 
mounted on Superfrost Plus slides (Menzel, Braunschweig, 
Germany) in four series, one for each neuropeptide or receptor, 
and dried for 2 days at 37oC. After deparaffinization and rehy-
dration, sections for AVP and MT2 were heated by microwave 
oven in citrate buffer pH 4.0 or Tris buffered saline (0.05M Tris 
and 0.15 M NaCl; pH 7.6), respectively, at 700 W. Sections were 
incubated in either rabbit antihuman-VIP (Netherlands Institute 
for Neuroscience, Amsterdam, the Netherlands) 1:1500, poly-
clonal rabbit antihuman-AVP (Netherlands Institute for Neu-
roscience) 1:800, polyclonal rabbit antihuman-MT1 (provided 
by R. Jockers) 1:200 or polyclonal rabbit anti-human-MT2-
antibody (provided by D. Angeloni and F. Fraschini) 1:4,000 
in Supermix (0,25% gelatin, 0,5% TritonX-100, 0.05M Tris 
and 0.15 M NaCl; pH 7.6). After overnight incubation, sections 
were incubated in biotinylated goat-antirabbit immunoglobulin 
G (Vector Laboratories Inc, Burlington, Ontario, Canada) 1:400 
followed by ABC-complex (Vector Laboratories Inc.) 1:800. 
Sections for MT1 and MT2 analysis were additionally incubated 
Table 1—Clinicopathologic characteristics of patients with Huntington’s disease and control subjects
NBB Sex Age Onset CTD MD PMD Fix CAG Cause of death
HD patients          
99–108 M 49 40 9:15 8 5:45 49 51 Cachexia 
03–047 F 50 35 18:25 6 5:40 55 47 Pneumonia
92–105 M 54 41 9:55 12 3:50 80 ND Sudden death
95–060 M 57 42 3:30 6 7:30 53 46 Cachexia
08–044 M 59 50 18:10 5 5:05 52 44 Legal euthanasia
01–128 M 61 39 10:55 11 10:25 48 43 Pneumonia
98–047 F 67 56 10:10 4 6:05 41 45 Legal euthanasia
99–120 M 79 54 19:00 10 6:15 34 44 Pneumonia 
Mean 60 45 12:25 8 6:19 52 46
SEM 3 3 1:57 1 0:41 5 1
Control subjects
98–006 (VIP, AVP) M 50 – 11:00 1 8:30 41 – Septic shock
00–090 (MT1, MT2) M 70 – 8:00 7 7:45 34 – Bladder carcinoma
97–127 F 49 – 3:30 4 13:30 165 – Cervix carcinoma
98–027 M 54 – 9:00 12 8:00 59 – Hepatocellular carcinoma
99–141 M 44 – 10:00 7 7:00 149 – Cardiac infarction
98–127 M 56 – 15:45 8 5:25 35 – Cardiac infarction
92–042 (VIP, AVP) M 61 – 21:00 4 13:50 52 – Esophageal carcinoma
97–143 (MT1, MT2) M 79 – 6:10 10 6:00 31 – Prostate carcinoma
98–036 F 69 – 6:15 3 9:25 31 – Cardiogenic shock
93–060 M 79 – 14:00 2 3:00 53 – Leaking aorta prosthesis
Mean (VIP, AVP) 58 – 11:18 5 8:35 73 –
Mean (MT1, MT2) 63 – 8:30 7 7:22 44 –
SEM (VIP, AVP) 4 – 1:57 1 1:18 19 –
SEM (MT1, MT2) 5 – 1:27 1 1:05 19 –
P value (VIP, AVP)  0.631
0.423
– 0.912 0.182 0.201
0.093
0.721
0.673
–  
P value (MT1, MT2)  0.751
0.603
– 0.522 0.892 0.371
0.403
0.831
0.783
–  
aFor the respective analyses different control patients had to be used (see (VIP, AVP), (MT1, MT2)) because of a lack of hypothalamic material. Unmarked 
control patients were used in all analyses. AVP, arginine vasopressin; CAG, mutant Huntingtin CAG repeat length; CTD, clock time of death; F, female; 
FIX, fixation time (in days); HD, Huntington’s disease; M, male; MD, month of death; MT, melatonin receptor; NA, not assessed; NBB, Netherlands Brain 
Bank number; PMD, postmortem delay (in hr); SEM, standard error of the mean; VIP, vasoactive intestinal polypeptide; Vonsattel, HD grading according to 
Vonsattel et al.14; 1Mann-Whitney-U test; 2Mardia–Watson test; 3Wilcoxon signed rank test.
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in thyramide 1:250 and reincubated in ABC-complex 1:800. 
Visualization of the immunoreaction product was achieved by 
incubation in 3,3′-diaminobenzidine (Sigma-Aldrich, St. Louis, 
MO) 0.5 mg/ml Tris buffered saline, containing 0.23% (w/v) 
nickel ammonium sulfate (Merck, Darmstadt, Germany) and 
0.01% (v/v) H2O2 (Merck). Specificity of all antibodies is de-
scribed in the following paragraphs.
In situ Hybridization
The methods used for the assessment of AVP and VIP mes-
senger RNA (mRNA) levels by in situ hybridization (ISH) are 
identical to those described before.18 Briefly, a 48-mer oligo-
nucleotide probe complementary to bases 411 to 458 of the 
human preprovasopressin precursor (GenBank # X03172.1) 
and a 48-mer oligonucleotide probe complementary to bases 
524 to 571 of human VIP (Genbank # NM003381.2) were 
used. Both probes were 3’-end labeled using terminal deoxy-
nucleotidyl transferase (Roche, Mannheim, Germany) and 
[35S] deoxyadenosine triphosphate (PerkinElmer, Burlingame, 
CA, Cat. # NEG612H) and purified by ethanol precipitation. 
Hybridization buffer consisted of 0.5 M NaCl, 1× Denhardt 
solution, 10 mM Tris-HCl, 1 mM EDTA, 10% dextran sul-
phate, 0.5 mg/ml yeast transfer RNA, 50% formamide, and 
200 mM dithiothreitol.
For analysis, every 25th (VIP) or 50th (AVP) (6 μm) sec-
tion along the rostrocaudal axis of the SCN was mounted on 
2% amino-alkyl-silane coated slides and dried at 58°C. After 
deparaffinization and rehydration, sections were microwave-
oven pretreated at 700 W in citrate buffer (pH 4). After de-
lipidation in phosphate buffered saline 0.1% Triton X-100, 
sections were hybridized in hybridization buffer with 1 × 
106 cpm of labeled AVP or VIP oligoprobe per slide, cover-
slipped and hybridized overnight at 42°C. After hybridization, 
sections were washed in sequential series of standard saline 
citrate and dehydrated in graded mixtures of 300 mM ammo-
nium acetate (pH 5.5) and absolute ethanol. Afterward, slides 
were dipped in photographic emulsion (NTB2; Carestream 
Health, Rochester, NY) at 42°C, dried and stored in a light-
tight box at 4°C for 17 days. Slides were developed for 2 min 
in Dektol Developer (Sigma), fixed in Kodak fixer (Sigma) at 
15°C, and counterstained with thionin.
Quantification
For an estimation of the total number of SCN neurons immu-
noreactive for VIP, AVP, MT1, or MT2 every 25th (6 μm thick) 
section throughout the entire SCN in rostrocaudal direction of 
each patient was used for analysis. All analyses were performed 
on the SCN in the left half of the hypothalamus for all subjects. 
Estimates were made using an image analysis system (Image-
Pro version 4.5, Media Cybernetics, Silver Spring, MD) con-
nected to a camera (JVC KY-F553CCD) and plain objective 
microscope (Zeiss Axioskop with Plan-NEOFLUAR Zeiss ob-
jectives, Carl Zeiss GmbH, Jena, Germany). Analysis consisted 
of two steps: area selection of the entire SCN and determining 
the number of immunoreactive neurons with a visible nucle-
olus, serving as a unique marker for individual neurons; and 
determination of the number of neuropeptide-immunoreactive 
neurons. Area selection and sampling were performed at 2.5× 
objective and the image was loaded into the image analysis sys-
tem and displayed on the monitor. Position and scanning stage 
using x and y coordinates were stored. In this image the area 
covered by the entire SCN was manually outlined and over this 
outlined area a grid was superimposed. From the respective grid 
fields x and y coordinates were stored and all individual images 
were retrieved at 40× objective on the image analysis monitor. 
In these images the manually outlined borders of the SCN area 
were visible and within these borders each neuropeptide-im-
munoreactive neuron containing a nucleolus was counted. This 
method has been described previously.18,19
The total number of SCN neurons in one-half of the hy-
pothalamus for each neuropeptide was estimated using a pre-
viously described technique based on multiplication of the 
neuronal counts by sample frequency (interval distance be-
tween sections) of the hypothalamus not requiring cross-sec-
tional area measurements of the SCN.19,20 Briefly, the amount 
of immunoreactive neurons per section, defined as An, was 
used for estimating the number of neurons within the nonas-
sessed sections on either side of An, defined as Dn. The value 
for Dn was calculated by adding the section number (dn) of 
An to the section number of the previous section (dn-1) and 
dividing it by two. The same procedure was repeated for the 
consecutive section (dn+1) and both figures were combined, so 
Dn = An * ((dn + dn-1) / 2 + (dn + dn+1) / 2). Finally, all counts 
for individual areas were added up (N = Σ Dn) for an estima-
tion of the total number of immunoreactive neurons per SCN. 
The mean (± standard deviation [SD]) number of sections 
quantified for each neuropeptide and receptor were as follows 
(patients with HD and control subjects, respectively): VIP 8.0 
± 2.6 and 11.6 ± 4.3 (P = 0.09); AVP 10.8 ± 3.1 and 12.0 ± 
3.7 (P = 0.37); MT1 9.4 ± 4.0 and 8.0 ± 2.1 (P = 0.46); MT2 
9.4 ± 4.0 and 8.0 ± 2.1 (P = 0.32). Neuronal cell counts or 
cross-sectional area analysis or neuronal density of the SCN on 
thionin-stained sections were not performed due to the inabil-
ity to recognize SCN neurons with certainty in thionin stain-
ing.13 We have tried to perform immunohistochemical staining 
for VPAC (VIP) receptor 2 without success on the paraffin 
embedded hypothalamic sections.
Quantitative analysis of the VIP and AVP mRNA signal in 
the SCN was performed in the same way as described previ-
ously and has also been described before.18,21 After retrieval of 
individual grid fields on the image analysis monitor a mask was 
superimposed on the silver grains. All profiles identified as neu-
rons were manually outlined. After correcting for background 
silver grains, the total mask area covered by the silver grains in 
these profiles was calculated. Finally, the total number of pro-
files expressing VIP and AVP mRNA in the SCN, total mask 
area of the silver grains in the profiles per SCN, and mean silver 
grains per profile were calculated as an estimate for the total 
amount of VIP and AVP mRNA in the SCN and the amount of 
VIP and AVP mRNA per SCN neuron. The mean (± SD) num-
ber of sections quantified were as follows (patients with HD 
and control subjects, respectively): VIP 5.5 ± 2.5 and 7.0 ± 1.6 
(P = 0.11); AVP 5.0 ± 1.1 and 6.3 ± 1.6 (P = 0.27).
All analyses for all neuropeptides were conducted by two ob-
servers independently of each other and blinded for the groups. 
For interrater reliability Cronbach alpha was used as a measure 
and was 0.960 – 0.962 for all analyses. The results in this study 
represent the mean of their observations.
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Antibody and Oligonucleotide Probe Specificity
Specificity of the VIP and AVP antibodies (Netherlands In-
stitute for Neuroscience), as well as the AVP oligonucleotide 
probe, has been described before.22-24 In addition, neither an-
tibody showed reactivity with spot-blots of the following 
peptides (20 pmol), formalin-fixed onto 0.2% gelatin-coated 
nitrocellulose paper,25 using an identical staining procedure as 
used for the hypothalamic sections: porcine neuropeptide Y(1–
36), agouti-related peptide (83–132), α-melanocyte stimulating 
hormone (MSH), β-MSH, γ-MSH, galanin, adrenocorticotropic 
hormone (1–39), luteinizing hormone releasing hormone, so-
matostatin-14 and -28, cocaine- and amphetamine-regulated 
transcript CART (106–129), oxytocin, corticotropin-releasing 
hormone, and melanin concentrating hormone. Moreover, the 
VIP antibody showed no reactivity with AVP peptide and the 
AVP antibody no reactivity with VIP peptide. VIP and AVP ISH 
probes were checked for cross homology with other known 
sequences using BLAST,26 which did not identify interfering 
sequences in the databases at the National Center for Biotech-
nology Information and National Library of Medicine. VIP and 
AVP ISH sense probes were used alongside the ISH antisense 
probes serving as negative control samples, producing no auto-
radiographic signal.
Specificity of the MT1 and MT2 antibody has been described 
before.27-29 Additionally, spot- blot testing confirmed that the an-
ti-MT2 antibody bound to synthetic human MT2 and not to spots 
containing vasopressin or oxytocin. Moreover, in human hypo-
thalamic sections no immunoreactivity could be seen when the 
MT2 antibody was preadsorbed with MT2 immunogenic peptide 
(Y-H Wu et al., Netherlands Institute for Neuroscience, 2009, 
unpublished data).
Statistical Analysis
All data are presented as median ± standard error of the mean 
unless otherwise specified. Differences between groups were 
statistically evaluated by the nonparametric Mann-Whitney U 
test (two-tailed). Intergroup differences in clock time and mo 
of death were evaluated using the Mardia-Watson test, whereas 
intergroup differences for dichotomous variables were evalu-
ated by chi-square. Spearman ρ was used to assess all correla-
tions. P < 0.05 was considered to be significant. All statistical 
analyses were performed using SPSS Statistics 17.0 (SPSS Inc, 
Chicago, IL).
RESULTS
Control subjects did not differ from patients with HD for 
any of the putative confounders. Groupwise and pairwise com-
parison yielded similar results, reflecting adequate matching 
(Table 1). The number of patients with HD and control subjects 
in each analysis (VIP/AVP and MT1/MT2) did not differ with 
respect to season or circadian time of death (i.e., either at day 
or at night) (P ≥ 0.14).
VIP and AVP Immunocytochemistry
Figure 1, A-D provides representative immunocytochemical 
stainings for VIP and AVP in HD patients and control subjects, 
showing reductions in both VIP-immunoreactive and AVP-
immunoreactive neurons in patients with HD. The number of 
VIP-immunoreactive neurons in the SCN of patients with HD 
(256 ± 122) was found to be 85% lower than that in control sub-
jects (1,679 ± 331) (P = 0.002). The number of AVP-immuno-
reactive neurons in the SCN of patients with HD (3,455 ± 588) 
was 33% lower than that in control subjects (5,154 ± 546, 
P = 0.027) (Figure 3).
MT1 and MT2 Immunocytochemistry
Figure 1, E-H provides representative immunocytochemical 
stainings for MT1 and MT2, showing no changes in MT1- or 
MT2-immunoreactive neurons between HD patients and con-
trol subjects. There was no significant difference between the 
total number of MT1- or MT2-immunoreactive neurons in HD 
patients (13,717 ± 1,523 and 6,605 ± 403, respectively) and 
control subjects (12,901 ± 2,203 and 4,161 ± 843, respectively) 
(P = 0.88 and 0.13, respectively) (Figure 4).
VIP and AVP mRNA Levels
Figure 2, A-D provides representative autoradiographs for 
VIP and AVP, showing no obvious differences between patients 
with HD and controls. Compared with control subjects, the to-
tal masking area of silver grains for VIP-mRNA (patients with 
HD 7.23 ± 5.27, control subjects 16.19 ± 1.11), as well as for 
AVP-mRNA (patients with HD 13.45 ± 6.71, control subjects 
17.75 ± 6.86) per SCN was unchanged (P = 0.14 and P = 0.58, 
respectively) (Figure 5). Furthermore, masked silver grains 
per cell profile was unchanged in patients with HD, both for 
VIP and AVP (P = 0.88 and P = 0.55, respectively). In addi-
tion, the number of cell profiles expressing VIP-mRNA or 
AVP-mRNA was similar in patients with HD (1,549 ± 600 and 
6,076 ± 1,419, respectively) and control subjects (4,351 ± 1,939 
and 6,265 ± 1,407, respectively) (P = 0.23 and P = 0.80, re-
spectively). The discrepancy between estimated neuronal num-
bers based on immunocytochemistry and ISH is due to the fact 
that for immunocytochemistry neurons with a visible nucleolus 
were counted, whereas in the ISH analyses all SCN neurons on 
individual sections were counted regardless of a nucleolus.
A positive correlation between the number of VIP-immuno-
reactive neurons and total masking area for VIP-mRNA was 
observed in control subjects (ρ = 0.833, P = 0.010), but was 
absent in patients with HD (ρ = 0.43, P = 0.29). No signifi-
cant correlations were observed between the number of AVP-
immunoreactive neurons and total masking area of AVP-mRNA 
(P = 0.57 for both patients with HD and control subjects).
DISCUSSION
To our knowledge, the current study is the first to report al-
tered morphology of the SCN in patients with HD. The num-
bers of both AVP and VIP neurons were significantly decreased 
in patients with HD, whereas the expression levels of AVP- and 
VIP-mRNA as well as the number of MT1 and MT2 neurons 
were unchanged. These findings suggest that alterations in the 
levels of two major regulatory neuropeptides in the SCN may 
contribute to sleep and circadian rhythm disturbances in pa-
tients with HD.
Circadian sleep disorders are frequently found in patients 
with HD2 and are partly mirrored in the R6/2 transgenic mouse 
model of HD, which shows a complete disintegration of cir-
cadian behavior.4 These mice show reduced levels of VIP and 
its receptor VPAC2 in the SCN,9 along with a marked disrup-
SLEEP, Vol. 36, No. 1, 2013 121 Suprachiasmatic Nucleus in Huntington’s Disease—van Wamelen et al
Figure 1—Representative immunocytochemical staining microscopic images for arginine vasopressin, vasoactive intestinal polypeptide and melatonin 1 and 
2 receptor in the suprachiasmatic nucleus. A, In patients with Huntington’s disease (HD), the number of vasoactive intestinal polypeptide-immunoreactive 
neurons was considerably lower than that in matched controls (shown in B) (P = 0.002). In addition, the number of arginine vasopressin-ir neurons in patients 
with HD (C) was lower than that in controls (shown in D) (P = 0.027). Melatonin 1 and 2 receptor-immunoreactive neurons were unchanged in patients with 
HD (E and G, respectively) compared with control subjects (F and H, respectively). HD patient NBB 01-128 and control subject NBB 98-127. Bars represent 
250 μm; bars in the inserts represent 100 μm.
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Figure 2—Representative in situ hybridization radiographs for vasoactive intestinal polypeptide and arginine vasopressin in the suprachiasmatic nucleus. 
mRNA levels of vasoactive intestinal polypeptide (A, patient with Huntington’s disease (HD); B, control subject) and arginine vasopressin (C, patient with HD; 
D, control subject) were unchanged in patients with HD (P = 0.14 and P = 0.58, respectively). HD patient NBB 01-128 and control subject NBB 98-127. Bars 
represent 250 μm; bars in the inserts represent 100 μm.
Figure 3—Total numbers of immunoreactive neurons for vasoactive 
intestinal polypeptide (VIP) and arginine vasopressin (AVP). Both the 
number of VIP and AVP immunoreactive neurons were significantly 
decreased in the suprachiasmatic nucleus of patients with Huntington’s 
disease (HD) (P = 0.002 and P = 0.027 respectively). Central bars 
represent the median.
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Figure 4—Total numbers of immunoreactive neurons for melatonin 1 
and 2 receptors. The number of melatonin 1 and 2 receptor (MT1 and 
MT2, respectively) immunoreactive neurons was unchanged in the 
suprachiasmatic nucleus in patients with Huntington’s disease (HD) 
(P = 0.88 and 0.13, respectively). Central bars represent the median.
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tion of two clock genes, mBmal1 and mPer2, both failing to 
exhibit circadian oscillation.4 Furthermore, circadian rhythm 
disturbances are also suggested by an onset delay in noctur-
nal rise in melatonin,3 as well as disrupted patterns of cortisol 
secretion in patients with early-stage HD.8 The decrease in the 
numbers of VIP and AVP neurons seems to confirm that cir-
cadian rhythm disturbances arise from pathology of the SCN. 
More specifically, our data suggest a posttranscriptional defect 
in neuropeptide production or a disturbed balance between pro-
duction and breakdown/release in SCN neurons of patients with 
HD. A discrepancy between AVP protein and mRNA levels has 
also been described in the SCN of patients with major depres-
sive disorder, where an increase in AVP protein levels was 
found together with a decrease in AVP mRNA,17 stressing that 
mRNA and protein levels do not necessarily have to go hand 
in hand. The difference between mRNA results in our cohort 
of HD patients and the R6/2 transgenic mice4 may potentially 
be explained by the large differences in CAG repeat lengths. In 
the patients with HD, the average CAG repeat length was ap-
proximately 46, whereas in the R6/2 rodent model of HD CAG 
repeat size was approximately 150.4 One may reason that the 
very long CAG repeats in rodents with HD may cause more se-
vere changes in hypothalamic neuropeptide expression. On the 
other hand, the precise effect of mutant huntingtin in neurons 
remains unknown. In a previous study it has been shown that 
the SCN is among the hypothalamic nuclei in patients with HD 
that contain the least amount of mutant huntingtin inclusions.8
Our findings suggest that sleeping disorders in patients with 
HD may partly stem directly from SCN pathology. Due to lack 
of polysomnographic data in our cohort of patients with HD it 
remains unknown, however, to what degree these SCN changes 
could contribute to sleep and circadian disorders in patients 
with HD. Other contributing factors may include a reduction in 
the expression of the hypothalamic neuropeptide orexin and al-
terations in the histaminergic system in patients with HD, both 
of which are of considerable importance for the regulation of 
sleep/wakefulness states.30,31 Part of the orexin reduction may 
be induced by a decrease in VIP in the SCN because orexin-con-
taining neurons in the lateral hypothalamus are innervated by 
VIP nerve fibers from the SCN, at least in rodents.32 However, 
although in R6/2 mice orexin levels are markedly decreased,33 
in a previous study including largely the same patients as in the 
current study, the number of orexin-producing neurons in the 
lateral hypothalamus was found to be reduced by approximate-
ly 30%.8 It is therefore uncertain whether this modest reduction 
in orexin levels could contribute to a major degree to sleeping 
disturbances in patients with HD,34 although additional (clini-
cal) studies directly assessing the association between orexin 
levels in the cerebrospinal fluid and sleep disturbances in pa-
tients with HD are needed to delineate the precise clinical rel-
evance of dysfunctional orexin signaling in patients with HD.
The changes that were observed in the SCN of patients with 
HD seem to be specific to the SCN because AVP is unchanged 
in other areas of the brain affected by HD, such as the hypotha-
lamic paraventricular nucleus (in the same patients with HD as 
in the current study),35 locus coeruleus, and substantia nigra.36 
Similarly, the decrease in VIP appears to be specific to the SCN 
because no change was observed in VIP concentrations in sev-
eral other brain areas in patients with HD.37 The changes in the 
SCN are similar to changes in the SCN concerning VIP and 
AVP in patients with Alzheimer disease38-40 and indicate that 
bright-light therapy may prove effective in improving circadian 
rhythmicity and cognitive functioning in patients with HD.41 
Similarly, melatonin (agonist) administration may prove effec-
tive in resetting circadian rhythmicity in the SCN through the 
MT1 and MT2 receptors,13,42 both of which were preserved in the 
SCN of our cohort of patients with HD. The unchanged expres-
sion of the MT1 and MT2 receptor seems to suggest that mela-
tonin levels are not decreased in HD patients and that merely 
the circadian timing of melatonin secretion is altered due the 
altered circadian output from the SCN.
Potential limitations of our study include the use of hypotha-
lamic material from patients with end-stage HD and the lack 
of data on sleep and circadian disorders in patients with HD. 
This lack of data results in the inability to directly link the ob-
served changes in the SCN to circadian abnormalities in pa-
tients with HD. We have, however, found in the same patients 
as in the current cohort, a disorder in the diurnal fluctuation 
of the expression of histidine decarboxylase (HDC). HDC is 
the key enzyme for histamine production, and the histaminer-
gic system is crucial for the regulation of circadian rhythm.43 
Furthermore, a potential limitation is the assessment of neu-
ronal numbers by counting of immunoreactive neurons. Using 
immunocytochemical markers it is impossible to distinguish 
between an actual loss of neurons in the SCN or a decrease in 
neurotransmitter levels without neuronal loss. On the mRNA 
level, however, we did not observe a significant change in the 
number of neurons expressing VIP or AVP. These latter findings 
suggest a posttranscriptional defect rather than a loss of SCN 
neurons in patients with HD, which is further corroborated by 
the unchanged number of neurons expressing MT1 and MT2. In 
addition, it has been shown that markers such as NeuN do not 
necessarily reflect the total number of neurons44 and that SCN 
borders can only be established on the basis of staining with im-
munocytochemical markers. These borders established by SCN 
markers such as AVP and VIP are activity-dependent, and SCN 
Figure 5—Total mask area of silver grains for vasoactive intestinal 
polypeptide (VIP) and arginine vasopressin (AVP) in the suprachiasmatic 
nucleus. For both VIP and AVP mRNA, the total mask area of silver 
grains in the suprachiasmatic nucleus was unchanged in patients with 
Huntington’s disease (HD) (P = 0.14 and P = 0.58, respectively). Central 
bars represent the median.
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volume and thus the total cell numbers seem, therefore, to fluc-
tuate with activity changes.39 In the R6/2 transgenic HD mice, 
the number of SCN neurons is unchanged.9 This potential post-
translational defect may be due to a decrease in prohormone 
convertases (PC), which are abundantly expressed in the rodent 
SCN and are involved in converting proVIP and proAVP into 
VIP and AVP, respectively.45 This finding seems to be supported 
by the observation that the number of PC 1/3 and PC2 express-
ing neurons are significantly reduced in the paraventricular and 
infundibular nucleus of the current patients with HD where 
mRNA levels of neuropeptides such as corticotrophin-releasing 
hormone and neuropeptide Y are unchanged or increased with 
decreased peptide levels.35
In conclusion, our findings provide evidence for severe SCN 
pathology in patients with HD, reflected by a substantial loss 
of VIP and AVP immunoreactivity, as well as an imbalance be-
tween protein and mRNA levels. No change was observed in 
MT1 and MT2 expression. Future studies should aim to discern 
potential phenotype differences in circadian and sleep disorders 
in HD patients and delineate the degree in which such differ-
ences would relate to the severity of SCN dysfunction.
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